Evidence map›Paper›PMID 34793741›Full record

ReviewLancet (London, England)2021

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.

Saad B Omer, Regina M Benjamin, Noel T Brewer, Alison M Buttenheim, Timothy Callaghan, Arthur Caplan, Richard M Carpiano, Chelsea Clinton, Renee DiResta, Jad A Elharake and 12 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06646744 (Safety Study About the mRNA Vaccines Against COVID-19 in Pediatric Patients), which is not on this map. Cited by 85 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 2 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06646744 completednot on this mapstarted 2022, after this paper: background citation

Safety Study About the mRNA Vaccines Against COVID-19 in Pediatric Patients (PEDIVACOV-HCSC)

TypeobservationalSponsorAna Belen Rivas PaternaRan2022 to 2023Enrolled2,100ConditionsCOVID-19 Vaccine Adverse ReactionArmsmRNA COVID-19 vaccine
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. COVID-19 Vaccine Decision-Making Among Black Pregnant and Postpartum Women.Journal of racial and ethnic health disparities · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 1 country.

Saad B OmerYale Institute for Global Health, Yale University, New Haven, CT, USA; Infectious Diseases Section, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA; Department of Epidemiology of Microbial Diseases, Yale University, New Haven, CT, USA; Yale School of Nursing, Yale University, Orange, CT, USA. Electronic address: saad.omer@yale.edu.
Regina M BenjaminGulf States Health Policy Center, Bayou La Batre, AL, USA.
Noel T BrewerDepartment of Health Behavior, Gillings School of Global Public Health, and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Alison M ButtenheimDepartment of Family and Community Health, University of Pennsylvania School of Nursing, and Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
Timothy CallaghanDepartment of Health Policy and Management, School of Public Health, A&M University, College Station, TX, USA.
Arthur CaplanLangone School of Medicine, New York University, New York, NY, USA.
Richard M CarpianoSchool of Public Policy, University of California, Riverside, CA, USA.
Chelsea ClintonClinton Foundation, New York, NY, USA; Mailman School of Public Health, Columbia University, New York, NY, USA.
Renee DiRestaStanford Internet Observatory, Stanford University, Stanford, CA, USA.
Jad A ElharakeYale Institute for Global Health, Yale University, New Haven, CT, USA; Infectious Diseases Section, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA.
Lisa C FlowersDepartment of Obstetrics & Gynecology, Emory University, Atlanta, GA, USA.
Alison P GalvaniCenter for Infectious Disease Modeling and Analysis, Yale University, New Haven, CT, USA.
Rekha LakshmananThe Immunization Partnership, Houston, TX, USA.
Yvonne A MaldonadoSchool of Medicine, Stanford University, Stanford, CA, USA.
SarahAnn M McFaddenYale Institute for Global Health, Yale University, New Haven, CT, USA; Infectious Diseases Section, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA.
Michelle M MelloSchool of Medicine, Stanford University, Stanford, CA, USA; Stanford Law School, Stanford University, Stanford, CA, USA; Freeman Spogli Institute for International Studies, Stanford University, Stanford, CA, USA.
Douglas J OpelDepartment of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; Seattle Children's Research Institute, Seattle, WA, USA; UC Hastings College of Law, University of California, San Francisco, CA, USA.
Dorit R ReissUC Hastings College of Law, University of California, San Francisco, CA, USA.
Daniel A SalmonInstitute for Vaccine Safety, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Jason L SchwartzDepartment of Health Policy and Management, Yale School of Public Health, Yale University, New Haven, CT, USA.
Joshua M SharfsteinDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Peter J HotezHagler Institute for Advanced Study at Texas A&M University, A&M University, College Station, TX, USA; Scowcroft Institute of International Affairs, Bush School of Government and Public Service Texas, A&M University, College Station, TX, USA; Texas Children's Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA; James A Baker III Institute for Public Policy, Rice University, Houston, TX, USA.
Johns Hopkins University · USStanford University · USYale University · USEmory University · USNew York University · USUNC Lineberger Comprehensive Cancer CenterUniversity of California Hastings College of the Law · USUniversity of California, Riverside · USUniversity of Pennsylvania · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Since the first case of COVID-19 was identified in the USA in January, 2020, over 46 million people in the country have tested positive for SARS-CoV-2 infection. Several COVID-19 vaccines have received emergency use authorisations from the US Food and Drug Administration, with the Pfizer-BioNTech vaccine receiving full approval on Aug 23, 2021. When paired with masking, physical distancing, and ventilation, COVID-19 vaccines are the best intervention to sustainably control the pandemic. However, surveys have consistently found that a sizeable minority of US residents do not plan to get a COVID-19 vaccine. The most severe consequence of an inadequate uptake of COVID-19 vaccines has been sustained community transmission (including of the delta [B.1.617.2] variant, a surge of which began in July, 2021). Exacerbating the direct impact of the virus, a low uptake of COVID-19 vaccines will prolong the social and economic repercussions of the pandemic on families and communities, especially low-income and minority ethnic groups, into 2022, or even longer. The scale and challenges of the COVID-19 vaccination campaign are unprecedented. Therefore, through a series of recommendations, we present a coordinated, evidence-based education, communication, and behavioural intervention strategy that is likely to improve the success of COVID-19 vaccine programmes across the USA.

Indexed as

Behavior TherapyCommunicationCOVID-19 VaccinesImmunization ProgramsSARS-CoV-2COVID-19HumansPoliticsUnited StatesVaccination RefusalCOVID-19 Vaccines

Identifiers

PMID34793741
PMCPMC8592561
OpenAlexW3214082094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.